e-learning
resources
Virtual 2021
06.09.2021
Screening, diagnosis, management and prognosis of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>
J. Nunes Caldeira Marinho Matos (Coimbra, Portugal), S. Rodrigues Sousa (Coimbra, Portugal), A. Figueiredo (Coimbra, Portugal), A. Pego (Coimbra, Portugal), F. Barata (Coimbra, Portugal)
Source:
Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer
Session:
Screening, diagnosis, management and prognosis of lung cancer
Session type:
E-poster
Number:
2189
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Nunes Caldeira Marinho Matos (Coimbra, Portugal), S. Rodrigues Sousa (Coimbra, Portugal), A. Figueiredo (Coimbra, Portugal), A. Pego (Coimbra, Portugal), F. Barata (Coimbra, Portugal). Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>. 2189
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro
Year: 2020
Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Year: 2020
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer
Source: Annual Congress 2007 - Novel genetic markers in pathology
Year: 2007
Survivin expression in non-small cell lung cancer
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Expression of ERCC1 in normal and tumor tissues in non-small cell lung cancer
Source: Annual Congress 2007 - Biology of thoracic malignancies
Year: 2007
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Differential cytokine expression in non-small cell lung carcinomas
Source: Eur Respir J 2007; 30: Suppl. 51, 512s
Year: 2007
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
The value of CD44 and MMP-2 expression in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 77s
Year: 2004
Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 770s
Year: 2006
Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer
Source: International Congress 2017 – Gene signatures in bronchial diseases
Year: 2017
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Choice of endogenous control for gene expression in nonsmall cell lung cancer
Source: Eur Respir J 2005; 26: 1002-1008
Year: 2005
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Prognostic value of p21 protein expression in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
Influence of overexpression of coagulantic and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept